Lilly's Levatol (penbutolol)
Executive Summary
Lilly's Levatol (penbutolol): Lilly is "continuing to assess marketing strategy "for the just-approved beta blocker licensed from Hoechst-Roussell ("The Pink Sheet, Jan. 4, p. 3). A Lilly spokesman said the company "has not determined when (Levatol) might be available." Lilly received approval for the one-a-day, non-cardioselective beta blocker on Dec. 31, nearly 4-1/2 years after NDA submission. Levatol is indicated for mild-to-moderate hypertension; recommeded dosage is two 10 mg tabs, once daily.